Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, July 3, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a l ...

Core Viewpoint - Hims & Hers Health has experienced significant volatility, with a recent decline of 16% in stock price, raising concerns among investors despite its strong fundamentals and growth potential [6][12]. Financial Performance - Hims & Hers reported revenue of $586 million for the latest quarter, marking a 111% year-over-year increase [14]. - The company achieved an all-time high of 2.4 million subscribers, reflecting a 38% annualized growth rate [14]. - Free cash flow for the quarter was reported at $50.1 million, nearly five times the $11.9 million from the same quarter the previous year [14]. Market Position and Strategy - Hims & Hers operates a subscription business model, providing stable and predictable cash flows, which is particularly valuable in volatile market conditions [13]. - The stock is currently trading at 66% of its 52-week high, suggesting a potential turnaround opportunity for investors [15]. Recent Developments - The stock initially surged over 100% following a partnership announcement with Novo Nordisk, which was later retracted, leading to the recent stock price decline [7][8]. - Despite the partnership's dissolution, the underlying reasons for the stock's previous rally remain intact, indicating continued growth potential [8][10]. Analyst Ratings and Forecast - The 12-month stock price forecast for Hims & Hers is $39.58, indicating a potential downside of 16.58% from the current price of $47.45 [12]. - Analysts have rated the stock as "Reduce," suggesting caution among investors [17].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of misleading statements and deceptive practices related to the promotion of illegitimate products, which may jeopardize its collaboration with Novo Nordisk [3]. Group 1: Allegations and Class Period - The class period for the lawsuit is from April 29, 2025, to June 23, 2025 [3]. - Allegations include that Hims engaged in the deceptive promotion and selling of knockoff versions of Wegovy®, risking patient safety [3]. - The lawsuit claims that the company's positive statements about its business and prospects were materially misleading and lacked a reasonable basis due to these practices [3]. Group 2: Shareholder Information - Shareholders who purchased HIMS shares during the class period are encouraged to register for the class action, with a deadline of August 25, 2025, to seek lead plaintiff status [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - Participation in the case incurs no cost or obligation for shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) ...

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and certain senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations and Allegations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk to sell the weight loss drug Wegovy, but allegedly misrepresented the nature of this partnership and compliance with FDA regulations [3][4]. Group 3: Stock Impact - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24, or over 34%, from $64.22 to $41.98 per share within three days [5].

Core Insights - The healthcare sector is highlighted as having significant growth opportunities, particularly in the weight loss drug market and gene editing technologies [2][4]. Group 1: Weight Loss Drug Market - Eli Lilly is positioned to potentially lead the GLP-1 agonist market, currently holding approximately 35% market share, while Novo Nordisk leads with 65% [4]. - The GLP-1 market is projected to grow to a $150 billion opportunity over the next decade, representing a tenfold increase from last year's sales [4]. - Eli Lilly is developing two promising drugs: Orforglipron, an oral GLP-1 pill, and Retatrutide, which targets multiple hormones and is in phase 3 studies [5][6]. - Analysts anticipate Eli Lilly will achieve 32% annualized earnings growth over the long term, despite a high price-to-earnings (P/E) ratio of nearly 65 [7][8]. Group 2: Gene Editing Technology - CRISPR Therapeutics is advancing its commercialization efforts for Casgevy, a therapy for sickle cell disease and beta-thalassemia, which is the first CRISPR-based treatment to receive FDA approval [10]. - The company has five additional therapies in clinical trials, indicating potential for significant growth if successful [11]. - Analysts project CRISPR Therapeutics will achieve $173 million in revenue next year, with an enterprise value of $2.2 billion, suggesting a reasonable price for the stock given its potential [12].

Core Viewpoint - Hims & Hers Health, Inc. is facing securities class action lawsuits due to allegations of failing to disclose material information during the class period, which has resulted in significant financial losses for investors [3][4]. Group 1: Legal Actions - Investors have until August 25, 2025, to file lead plaintiff applications in the ongoing securities class action lawsuits against Hims & Hers Health, Inc. for purchases made between April 29, 2025, and June 23, 2025 [1][2]. - The lawsuits are pending in the United States District Court for the Northern District of California, with the first case filed being Sookdeo v. Hims & Hers Health, Inc. [5]. Group 2: Company Issues - Novo Nordisk terminated its partnership with Hims on June 23, 2025, citing violations of laws regarding the sale of compounded drugs and concerns over patient safety due to deceptive marketing practices [4]. - Following the announcement of the partnership termination, Hims' share price dropped by $22.24, or 34.6%, closing at $41.98 per share on June 23, 2025, amid unusually high trading volume [4]. Group 3: Law Firm Background - Kahn Swick & Foti, LLC, the law firm handling the lawsuits, is recognized as one of the top boutique securities litigation firms in the U.S., serving both institutional and retail investors [5].

Company Overview - Hims & Hers Health, Inc. is a telehealth and online pharmacy company that provides prescription and over-the-counter medications, mental health services, and personal care products through a direct-to-consumer platform, connecting users with licensed healthcare professionals in the U.S. and the U.K. [3] Allegations and Impact - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Hims, stemming from allegations of providing potentially misleading business information to the investing public [1] - On April 29, 2025, Novo Nordisk announced it would sell its weight loss drug Wegovy through Hims' telehealth platform, but on June 23, 2025, Novo Nordisk terminated its partnership with Hims due to concerns about Hims' compliance with laws governing the sale and marketing of compounded drugs [4] - Following the termination of the partnership, Hims' stock price fell by $22.24 per share, or 34.63%, closing at $41.98 per share on June 23, 2025 [4]

Core Viewpoint - Hims & Hers Health Inc. is under investigation for potential securities fraud related to misleading statements made to investors during a specified Class Period [1][2]. Group 1: Investigation Details - Berger Montague is investigating whether Hims & Hers violated federal securities laws by making false or misleading statements during the Class Period from April 29, 2025, to June 22, 2025 [1]. - Following the termination of a partnership with Novo Nordisk due to unauthorized marketing and sale of compounded semaglutide drugs, Hims & Hers' shares dropped over 34% on June 23, 2025 [2]. - A complaint has been filed alleging material misstatements and omissions in violation of federal securities laws [2]. Group 2: Legal Action - Investors have until August 25, 2025, to seek appointment as lead plaintiff in the class action lawsuit, which allows them to direct the case and advocate for other harmed investors [3].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in its stock price following the termination of its partnership with Novo Nordisk [2][3]. Group 1: Company Actions and Events - On April 29, 2025, Hims announced a collaboration with Novo Nordisk to sell a bundled offering of Wegovy on its platform [2]. - On June 23, 2025, Novo Nordisk terminated its partnership with Hims, citing deceptive promotion and safety risks associated with Hims' products [2]. - Following the termination announcement, Hims' share price fell by $22.24, or 34.6%, closing at $41.98 per share on June 23, 2025 [2]. Group 2: Lawsuit Details - The class action lawsuit alleges that Hims made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3]. - Specific allegations include Hims' engagement in deceptive practices regarding the sale of knockoff Wegovy versions and the risk of partnership termination with Novo Nordisk [3]. - The lawsuit claims that Hims' positive statements about its business lacked a reasonable basis due to these undisclosed risks [3].